LXRX logo
LXRX NASDAQ US

Lexicon Pharmaceuticals, Inc. - Common Stock

Healthcare · Pharmaceuticals Website · IPO Apr 2000
$1.59
▼ $-0.05 (-3.05%)
Vol 2.3M
6
Quality Score
fail
Mkt Cap
$417.9M
ROE
-52.9%
Margin
-96.8%
D/E
47.03
Beta
0.95
52W
$0–$2

Wall Street Consensus

11 analysts · Apr 2026
3
Strong Buy
5
Buy
3
Hold
0
Sell
0
Strong Sell
72.7%
Buy Rating

Price Chart

Similar Stocks

SGP
SpyGlass Pharma Inc
RLMD
Relmada Therapeutics Inc
$354.2M
ARVN
Arvinas Inc
$761.7M
ETON
Eton Pharmaceuticals Inc
$453.5M
ESPR
Esperion Therapeutics Inc
$884.5M
LBRX
LB Pharmaceuticals Inc
$563.2M
ZVRA
Zevra Therapeutics Inc
P/E 14.3
$504.4M
CRMD
CorMedix Inc
P/E 5.6
$916.3M

Earnings

Beat rate: 100.0%
Quarter EPS Est EPS Act Surprise
Dec 2025 $-0.07 $-0.04 +$0.03
Sep 2025 $-0.07 $-0.04 +$0.03
Jun 2025 $-0.08 $0.01 +$0.09
Mar 2025 $-0.10 $-0.07 +$0.03

Fundamentals Trend

Metric 2025-06-30 2025-09-02 2025-10-02 2025-11-03 2025-12-03 2026-01-02
ROE (TTM) -83.6% -83.6% -83.6% -83.6% -52.9% -52.9%
P/E (TTM) — — — — — —
Net Margin 11.3% -206.4% -206.4% -206.4% -96.8% -96.8%
Gross Margin 99.9% 99.2% 99.2% 99.2% 99.4% 99.4%
D/E Ratio 43.35 43.35 43.35 43.35 47.03 47.03
Current Ratio 4.16 4.16 4.16 4.16 5.64 5.64

Key Ratios

ROA (TTM)
-26.7%
P/S (TTM)
5.90
P/B
1.8
EPS (TTM)
$-0.19
CF/Share
$-0.76
Rev Growth 3Y
+369.7%
52W High
$1.66
52W Low
$0.28
$0.28 52-Week Range $1.66

How does LXRX compare to Pharmaceuticals peers?

Peer group: Micro-cap Pharmaceuticals (All) · 171 companies

LXRX AARD ACB ACRS ADIL

LXRX valuation vs Pharmaceuticals peers

P/E ratio
—
▼ 0% below peers (22.4)
vs Peers
vs Industry
Undervalued
P/S ratio
5.9
▲ 19% above peers (5.0)
vs Peers
vs Industry
Pricier
P/B ratio
1.8
▼ 14% below peers (2.1)
vs Peers
vs Industry
Fair value
Div yield
—
▼ 0% below peers (2.0%)
vs Peers
vs Industry
Low yield

LXRX profitability vs Pharmaceuticals peers

ROE
-52.9%
▲ 3% above peers (-54.3%)
vs Peers
vs Industry
In line
Net margin
-96.8%
▼ 104% below peers (-47.4%)
vs Peers
vs Industry
Weak
Gross margin
99.4%
▲ 46% above peers (68.3%)
vs Peers
vs Industry
Below avg
ROA
-26.7%
▲ 29% above peers (-37.4%)
vs Peers
vs Industry
Below avg

LXRX financial health vs Pharmaceuticals peers

D/E ratio
47.0
▲ 2954% above peers (1.5)
vs Peers
vs Industry
High debt
Current ratio
5.6
▲ 68% above peers (3.4)
vs Peers
vs Industry
Below avg
Beta
1.0
▲ 1% above peers (0.9)
vs Peers
vs Industry
Less volatile

LXRX fundamentals radar

LXRX Peer median Industry

LXRX profitability vs leverage

Bubble size = market cap · X = net margin · Y = D/E ratio

LXRX vs peers: key metrics

Latest News

H.C. Wainwright Remains a Buy on Lexicon Pharmaceuticals (LXRX)
Yahoo Finance · Mar 22